Pharmaceutical company Advicenne recently announced it has made significant strides in marketing its flagship product Subnayal in Europe, according to a press release.
The company highlighted the strategy it used to develop and improve the commercialization of Subnayal's innovative treatment distribution across the continent.
Sibnayal™ is the first and only currently label-approved drug for the treatment of Distal renal tubular acidosis (dRTA) in adults, adolescents, and children aged one year and older.
"Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that it has made significant progress in the marketing and distribution of ADV7103 (Sibnayal™)," the company stated in the release. "The company has completed the first round of pricing negotiations in the United Kingdom (UK) and has signed its first two distribution agreements for Sibnayal™, which covers 25% of European patients affected by the disease."
A quarter of the company's first round of pricing negotiation is currently taking place in the UK.
"We are pleased to have accomplished these first marketing and distribution milestones in the UK and the EU (European Union) which are key in Sibnayal’s commercial journey," Didier Laurens, CEO of Advicenne said in the release. "The NHS (National Health Service) is setting a benchmark price which highlights the benefit of SibnayalTM in offering a new therapeutic option which improves the quality of life of patients suffering from dRTA. We are also delighted to have signed collaboration agreements with TwinPharma for Benelux and ExCEEd Orphan for Central and Eastern Europe – two of the most successful rare disease specialists. These agreements will make Sibnayal™ available to about 25% of the 30,000 European dRTA patients and we are pleased and honored to make this treatment available as quickly as possible."
The cost of 8mEq and 24mEq dosages are £120 and £360. To meet the terms of the distribution agreement, treatment for dRTA patients must cost more than 10,000 euros.